8-K Announcements
6Material company update
Dec 29, 2025·SEC
Material company update
Dec 8, 2025·SEC
Material company update
Nov 25, 2025·SEC
Clearside Biomedical faces a precarious financial outlook characterized by a heavy reliance on volatile milestone payments and a rapidly depleting cash reserve. While the company continues to prioritize R&D investment, the lack of consistent commercial revenue...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Benchmark CLSD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Clearside Biomedical, Inc. (CLSD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.41 | $2.15M | -0.06 | -79.77% | -2064.42% | — | — | |
| $6.50 | $1.42B | -4.58 | -18.67% | -579.1% | -59.87% | — | |
| $4.36 | $90.9M | -0.66 | -72.22% | — | — | — | |
| $2.29 | $250.05M | -1.14 | — | — | -5.76% | — | |
| $11.46 | $962.94M | -3.39 | — | — | -159.32% | — | |
| $14.68 | $1.7B | -12.03 | 8.28% | -21.25% | -44% | — |
Clearside Biomedical, Inc. (CLSD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Clearside Biomedical, Inc. (CLSD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 29, 2025·SEC
Dec 8, 2025·SEC
Nov 25, 2025·SEC
Get notified when CLSD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Clearside Biomedical, Inc. (CLSD) stock FAQ — growth, dividends, profitability & financials explained
Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue for fiscal year 2024.
Clearside Biomedical, Inc. (CLSD) saw revenue decline by 79.8% over the past year.
Clearside Biomedical, Inc. (CLSD) reported a net loss of $26.0M for fiscal year 2024.
Clearside Biomedical, Inc. (CLSD) had negative free cash flow of $21.7M in fiscal year 2024, likely due to heavy capital investments.